NCT07150117 Cycling-Based Aerobic Exercise Intervention for Individuals With Chemotherapy-Induced Peripheral Neuropathy (CIPN)
| NCT ID | NCT07150117 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-01-26 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-01-26 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CYCLE-CIPN is a proof-of-concept study designed to evaluate whether a prescribed aerobic exercise intervention has the potential to reduce the symptoms and functional impact of CIPN. The small number of participants in the proposed study will allow us to make decisions on the feasibility ("go/no-go") of a future larger-scale trial. The protocol will assess feasibility and acceptability through recruitment, completion, adherence, program satisfaction, and safety. The study will also evaluate CIPN symptoms using both patient-reported and objective outcome measures, as well as fitness and quality of life outcomes. We aim to recruit 30 participants. The Health Research Board of Alberta Cancer Committee has approved this study. Participants will participate in a stationary cycling-based aerobic exercise program biweekly for 12 weeks. Exercise sessions will be supervised and progressive, between 30 and 60 minutes each.
Eligibility Criteria
Inclusion Criteria: * 18 years or older * Cancer diagnosis stage I to III * CIPN: grade 1 (mild) * Receiving or have received chemotherapy treatment for cancer * Speak, read and understand English Exclusion Criteria: * Medical conditions that cause additional neuropathy symptoms (i.e. diabetes) * Any uncontrolled medical conditions * Will undergo surgery or radiation therapy during the study period * Are already receiving an aerobic exercise training program * Are already participating in an exercise-based research study * Are unable to provide signed informed consent
Contact & Investigator
Margaret L McNeely, PhD
PRINCIPAL INVESTIGATOR
University of Alberta
Frequently Asked Questions
Who can join the NCT07150117 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07150117 currently recruiting?
Yes, NCT07150117 is actively recruiting participants. Contact the research team at frmace@ualberta.ca for enrollment information.
Where is the NCT07150117 trial being conducted?
This trial is being conducted at Edmonton, Canada.
Who is sponsoring the NCT07150117 clinical trial?
NCT07150117 is sponsored by University of Alberta. The principal investigator is Margaret L McNeely, PhD at University of Alberta. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.